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The aim of the study was to investigate whether
various beta-cell stimulatory drugs, given neona-
tally, influence the incidence of diabetes in BB rats.
Newborn BB rats were treated twice daily for 6 days
and diabetes development was observed during the
following 200-day study period. Compared to a
diabetes incidence of 63.8% in 163 control BB rats
which received saline or were untreated, the percen-
tage of experimental BB rats that developed diabetes
was as follows in the different subgroups: arginine-
glucose: 47% (n 73, p < 0.02); glucagon: 37% (n
93, p < 0.0001); tolbutamide-glucose: 36% (n 58,
p < 0.0005); and theophylline-glucose: 39% (n 41,
p<0.005). A long-term arginine-glucose treatment
was not superior to the shorter neonatal treatment.
Histological examination revealed a higher degree of
insulitis in diabetic than in non-diabetic animals
but no difference according to the kind of treatment
was observed. Finally, we found that the diabetes
incidence in BB rats was higher in the first litter
compared to subsequent litters (p=0.04). Thus,
neonatal treatment with various beta-cell stimula-
tory agents reduces diabetes incidence in BB rats.
The theory behind the study, that the treatment
accelerates beta-cell maturation leading to increased
immunological tolerance towards beta cells, is
discussed.
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INTRODUCTION
The idea of neonatal stimulation of beta cells in
BB rats and NOD mice in order to reduce the
diabetes incidence (Buschard et al., 1990) is
inspired by two observations.
Firstly, Type 1 diabetes is less frequent in
children of Type 1 diabetic mothers than in
children of diabetic fathers (Warram et al., 1984;
Tilli and K6bberling, 1987; Rjasanowski et al.,
1990); in other words: a Type 1 diabetic
pregnancy seems to partially protect against
development of Type I diabetes in the offspring.
Even if the mothers develop Type 1 diabetes
during pregnancy, diabetes is infrequent among
the children (Buschard et al., 1989). Interestingly,
a growing knowledge indicates that if the
mothers develop Type 1 diabetes after the
pregnancy, the children seem to have the same
diabetes risk as children of diabetic fathers
(Warram et al., 1984; Lorentzen et al., 1998).
Secondly, antigen expression of the beta cells
seems to be dependent on their functional state;
at a high function there is a high expression. This
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has been found for the antigens corresponding
to the (monoclonal) antibodies IC2 (Buschard
et al., 1988; Aaen et al., 1990), A2B5 (Aaen et al.,
1990; Eisenbarth et al., 1982), R2D6 (Appel et al.,
1989), and ICA (McCulloch et al., 1991), and for
GAD (Hao et al., 1994) and 64kDa antigen
(K/impe et al., 1989).
Normally, beta cells are immature at birth
(Freinkel et al., 1984; Grasso et al., 1973;
Otonkoski et al., 1988) whereas in the diabetic
pregnancy the beta cells mature earlier (Heding
et al., 1980). Since diabetes is an autoimmune
disease resulting from a break of self tolerance,
we wanted to investigate whether neonatal beta-
cell stimulation, and thereby early maturation of
the beta cells like in the diabetic pregnancy with
fetal hyperglycemia, could lower the diabetes
incidence. Normally, neonatal beta cells are
insensitive to glucose during the first two weeks
of life (Otonkoski et al., 1988) but sensitive to
arginine, glucagon, and theophylline (Otonkos-
ki, 1988). Therefore, in this study we used the
three mentioned agents as well as tolbutamide;
all these molecules are non-toxic to mammalians
and they have different mechanisms of action.
The optimal duration of the treatment is
unknown. Therefore, besides short-term stimu-
lation which we arbitrarily chose to be twice
daily for six days, we also performed a pro-
longed experiment with treatment weekly
throughout the entire study.
METHODS
Neonatal Stimulation of Beta Cells
BB rats (Mollegaard, L1. Skensved, Denmark)
were paired in our Institute. No diabetic BB rats
were used as fathers, or as mothers during the
pregnancy and the weaning period. From the
day of birth and during the 5 following days the
newborn rats were treated twice daily (morning
and evening) with intraperitoneal or subcuta-
neous injections of 100 tl sterile water or saline
to which had been added: 7.5mg (1.1 g/kg body
weight) L-arginine (Sigma, St. Louis, USA) and
2.5mg (0.4g/kg BW) glucose (n=73 BB rats);
0.01mg(1.4mg/kgBW) glucagon (Novo Nor-
disk, Bagsvaerd, Denmark) and 5mg (0.7g/kg
BW) glucose (n=43); 0.02mg (2.8mg/kg BW)
glucagon zinc protamine (Novo Nordisk)
(n 50);1.25mg (180mg/kg BW) tolbutamide
(Hoechst, Frankfurt, Germany) and 10mg
(1.4g/kg BW) glucose (n=58); or 0.140mg
(20mg/kg BW) theophylline and 10mg (1.4g/
kg BW) glucose (n=41). The dosage of the
different compounds was arbitrarily chosen
within the limits of possible pharmacological
treatment. Addition of glucose was performed
in order to avoid any risk of hypoglycemia and
the amount was arbitrary as well. Control BB
rats were given saline i.p. (n=46), saline s.c.
(n 49), or were untreated (n 68).
The animals were weaned after 3 weeks and
allowed free access to chow and water. The
animals were observed daily, and weighed and
examined weekly for glucosuria (TesTape, Lilly,
Indianapolis, USA). Diabetes was diagnosed if at
least ++ glucosuria (1/4%)with > 10% weight
loss (compared to the previous week) was
observed. When this occurred the animals were
sacrificed by CO2 anesthesia and the blood
glucose values were measured. The study was
terminated at day 200.
In a long-term arginine-glucose treatment
group (n=31), L-arginine (75mg/ml)-glucose
(25 mg/ml) was given i.p. twice a day from the
day of birth and during the 5 following days,
afterwards once a week to the end of the study at
a dose of 100 tl/6 g BW up to a maximum dose
of 1000 tl. Control BB rats (n =36) were corre-
spondingly given saline.
Histological Studies
The paraffin-embedded pancreases were cut
into 4 tm sections and stained with hematoxylin
and eosin. An area of 11.4mm2 (11,400,000 tm2)NEONATAL TREATMENT WITH BETA-CELL AGENTS 3
in sections from each BB rat was scored in a
Leitz Wetzler dialux microscope equipped with
a Microvid image analysis system for the degree
of insulitis. Insulitis was scored semiquantita-
tively with Grade 0 denoting morphologically
unaffected islets, Grade 1 a very disperse intra-
insular infiltration of mononuclear cells, Grade 2
a more pronounced intra-insular infiltration
with either disperse or small clusters of mono-
nuclear cells and, finally, Grade 3 denoting islets
dominated by infiltrating mononuclear cells. In
Grade 3 the islets often show an altered
architecture and pyknotic cell nuclei. Islets with
peri-insular infiltration were placed in group 2
or 3 depending on the intra-insular infiltration of
mononuclear cells. Ten islets were scored in
each section and the average was calculated and
considered the final score of insulitis.
Statistics
ences between the various treated groups, and
their incidence curves were comparable. On the
other hand, all the experimental groups each
displayed a substantially lower diabetes inci-
dence than the 163 control BB rats of which
63.8% developed diabetes during the 200 days
observation period.
In Figure 2 the rats are divided according to
sex. The curves for the male and female rats
were similar for both the treated and control
animals, respectively, apart from a slightly lower
incidence of diabetes for the female BB rats at
the end of the study (treated BB rats: 41.1% vs.
38.6%, p>0.10, control BB rats: 67.6% vs. 60.9%,
p > 0.10).
Figure 3 shows the result of the extended
arginine-glucose treatment. The diabetes inci-
dence was significantly lower (p=0.04) for the
long-term treated animals than for the control
group.
The cumulative diabetes incidence observed in
each test group was calculated by Kaplan-Meier
estimation and statistical significance was eval-
uated by the log-rank (Peto) test. Differences in
diabetes incidence between groups of litters
were compared by means of t-test after a
variance stabilizing angle transformation of the
frequency within litters (Hald, 1957). Other
differences were estimated by the Mann-Whit-
ney test. Spearman’s rank correlation test was
used for the calculations of the coefficient of
correlation. Data are presented as mean 4-SEM.
RESULTS
Diabetes Incidence
Histological Studies
The result of the examination of the islets for
insulitis is shown in Table II. All the groups of
diabetic rats had significantly higher scores than
the non-diabetic rats. There were no differences
between the various experimental groups. How-
ever, it should be noticed that overall the degree
of insulitis was modest and massive insulitis
was only rarely seen. Control rats with early
diabetes development (before day 100) showed
similar degrees of insulitis as rats that became
diabetic after day 100 (1.44-0.1 vs. 1.14-0.1,
(p > 0.10). Likewise, no differences were seen for
treated diabetic animals (1.2 4- 0.2 vs. 1.1 4- 0.1
insulitis score).
The results of the different neonatal treatments
can be seen in Figure 1 and Table I. The
experimental BB rats received either arginine,
glucagon, tolbutamide or theophylline, and the
diabetes incidences were found to remain
between 30% and 47%. There were no differ-
Studies of Litters and Sex
Litters contained more female than male BB rats
in both the experimental and control groups
(42.3% and 43.6% males, respectively). Litter
sizes were similar in the experimental and the4 K. BUSCHARD et al.
FIGURE Cumulative diabetes incidence for the different treated groups (arginine-glucose glucagon tolbutamide-
glucose theophylline-glucose and control group of BB rats (--).
TABLE Number of animals and cumulative diabetes incidence at 200 days of age in the different treatment groups
Number of BB rats Diabetes incidence at 200 days of age (%) Difference from controls
Arginine-glucose 73 47 p < 0.02
Glucagon-glucose 43 42 p < 0.02
Glucagon zink protamine 50 30 p < 0.00005
Tolbutamide-glucose 58 36 p < 0.0005
Theophylline-glucose 41 39 p < 0.005
Controls 163 64
control group (6.6 4-0.5 and 6.5 4-0.7 rats, re-
spectively). There was no association between
litter size and diabetes incidence in any of the
groups. Furthermore, the mean litter size was
the same in the different litter generations.
To investigate the correlation between litter
number and diabetes incidence, the 25 control
litters with a total of 163 offspring were divided
into a group of 12 first litters and a group
of 13 second or later litters (Tab. III). The
overall diabetes incidences were 57/77=0.74
and 47/86=0.54, respectively. By comparison
of these incidences after angle transformation
the difference was found statistically significant
(p=0.04). The mean litter number was
1.754-0.20 for the experimental BB rats and
1.964-0.24 for the controls, which was not
significantly different.oI
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FIGURE 2 Cumulative diabetes incidence for male and female BB rats in the collective neonatally treated group (M F
and in the control group (M m; F ).
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FIGURE 3 Cumulative diabetes incidence for long-term arginine-glucose treated BB rats and their saline treated controls6 K. BUSCHARD et al.
TABLE II Average degree of insulitis 4-SEM in the different groups. Number of investigated animals is indicated in brackets.
Significance tests refer to the result of non-diabetic control BB rats
Non-diabetic rats Diabetic rats
Control BB rats
Treated BB rats
Long-term treated BB rats
0.6 + 0.1 (70)
0.84-0.1 (158) p<0.005
0.7+ 0.2 (9) n.s.
1.2 4- 0.1 (87) p < 10
-7
1.1 4- 0.1 (88) p < 10
-6
1.1 4-0.2 (15) p<0.005
TABLE III Litter size and diabetes incidence for the first and second-fifth litter numbers, respectively, among the diabetic
control BB rats
Litter number Litter size diabetes incidence (%)
First 2 2 7 5 2 10 10 3 6 13 9 8
50 50 86 80 50 50 80 67 67 69 89 100
Second-fifth 9 11 8 6 6 3 3 11 13 4 3 4
67 45 88 67 83 33 67 64 54 50 0 0
5
20
DISCUSSION
The present investigations have shown in large-
scale experiments that the diabetes incidence in
BB rats can be reduced by neonatal injections of
various agents known to stimulate insulin
secretion by different mechanisms. These agents
include arginine, glucagon, and for the first time
tolbutamide and theophylline. Also, for long-
term treatment with arginine-glucose a reduc-
tion in diabetes incidence is found, but this
treatment is not superior compared with the
proper neonatal one.
Until now only a few other studies have dealt
with the concept of neonatal beta-cell stimula-
tion. In a barrier-confined colony of BB rats with
a high diabetes incidence, this was moderately
but significantly reduced and the onset of
diabetes delayed after neonatal treatment with
arginine and glucose combined, but given only
once a day (Hansen et al., 1993). In NOD mice
the diabetes incidence has been found by our
group to be reduced by neonatal treatment with
glucose (Bock et al., 1991). We have as yet no
explanation for the discrepancy between NOD
mice and BB rats in which glucose treatment per
se does not significantly alter the diabetes
incidence (Buschard et al., 1990). Interestingly,
female NOD mice treated with neonatal injec-
tions the first 6 days of life with I mg arginine
and 0.5mg glucose combined displayed diabetes
earlier and with a higher incidence (Senecat et al.,
1994). Obviously, the outcome of arginine on the
one hand and of pure glucose on the other is
different, and the effect of these compounds on
beta-cell maturation should be studied with
molecular biological methods. In another ap-
proach of early beta-cell stimulation, 4-week old
NOD female mice were fed with 1 to 1.75g
glucose orally per day until the age of 30 weeks;
at that time 37% of the experimental mice had
developed diabetes compared to 86% of the
controls (Vardi and Buschard, 1995). Regarding
tolbutamide, treatment starting at the time of
weaning has resulted in a reduced diabetes
incidence in NOD mice (Williams et al., 1993);
although different in time of treatment this
study may be comparable with our neonatal one.
The precise mechanism behind the observed
reduction of diabetes incidence and delayed
onset of the disease in BB rats is unknown. The
theory behind the study is that the antigenic self
of the beta cells is less well established because
the cells are immature at birth and not fully
developed until later in life; antigenic differ-
ences should then exist between young and
adult beta cells, which has indeed been con-
firmed. A 38 kDa protein, reacting with sera
from diabetic BB rats, is present in adult but not
in neonatal BB rat islet cells (Ko et al., 1994).NEONATAL TREATMENT WITH BETA-CELL AGENTS 7
Furthermore, adult but not neonatal islets are
destroyed after transplantation to diabetic BB
rats (Ihm et al., 1991). Another study measured
in vitro cytotoxicity mediated by mononuclear
spleen cells from newly diabetic BB rats and
found a significantly lower cytotoxicity towards
islet cells from BB rats < 4 days old than towards
islet cells from adult insulitis-free BB rat islets
(Ekblond et al., 1995). Islet cell maturation in BB
rats-as evidenced by sensitivity to cytotoxi-
city-was not seen before the age of 21 days after
birth (Ekblond et al., 1995).
The finding in the present study-that the
litter sequence number seems to influence the
diabetes incidence in BB rats-is to our knowl-
edge a new observation which may reflect that,
among diabetes-prone rats, the risk of develop-
ing diabetes in the offspring decreases with
maternal age; this parallels findings in humans
(Warram et al., 1991).
It has been suggested that the protection of the
diabetic pregnancy against development of
diabetes in the offspring may be due to a direct
immunological mechanism (Dosch et al., 1993).
This might be mediated by placental transfer of
autoantibodies which in the fetus, according to
the immunological network theory, might raise
specific regulator cells. However, offspring of
Type 2 diabetic mothers also have lower
incidence of Type 1 diabetes compared to
children of Type 2 diabetic fathers (Green et al.,
1994) and Type 2 diabetic mothers do not
display autoantibodies. This may support the
mechanism involving early stimulation of the
beta-cells as suggested in this study.
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